1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma
    Journal Article

    Hanna, G. J.; Ahn, M. J.; Muzaffar, J.; Keam, B.; Bowles, D. W.; Wong, D. J.; Ho, A. L.; Kim, S. B.; Worden, F.; Yun, T.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma
    Review

    Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
    Blood Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Development of a p-hydroxybenzyl-alcohol-linked glutamate prodrug for activation by pseudomonas carboxypeptidase G2
    Journal Article

    Lee, J. P.; Corless, B. C.; Gardner, T. J.; Scheinberg, D. A.; Tan, D. S.
    Organic Letters (2023)

    Fulltext@MSK | Save
  • MMP-responsive nanomaterials
    Review

    Son, J.; Parveen, S.; MacPherson, D.; Marciano, Y.; Huang, R. H.; Ulijn, R. V.
    Biomaterials Science (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical (131)I-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Laccetti, A. L.; Bodei, L.; O'Donoghue, J. A.; Weber, W. A.; Morris, M. J.
    Clinical Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Research Letter

    Parisi, R.; Cowen, E. A.; Gu, S.; Dusza, S.; Pulitzer, M.; Geyer, M. B.; King, A. C.; Markova, A.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Current treatment options in relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: A review
    Review

    Islam, P.
    Current Treatment Options in Oncology (2023)

    Fulltext@MSK | Save
  • Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer
    Journal Article

    Oliveira, G.; Egloff, A. M.; Afeyan, A. B.; Wolff, J. O.; Zeng, Z.; Chernock, R. D.; Zhou, L.; Messier, C.; Lizotte, P.; Pfaff, K. L.; more...
    Science Immunology (2023)

    Fulltext@MSK | Save
  • Chemotherapy-induced taste alteration
    Review

    Penna, S.
    Clinical Journal of Oncology Nursing (2023)

    Fulltext@MSK | Save
  • MAPK-negative feedback regulation confers dependence to JAK2(V617F) signaling
    Journal Article

    Kesarwani, M.; Kincaid, Z.; Azhar, M.; Menke, J.; Schwieterman, J.; Ansari, S.; Reaves, A.; Deininger, M. E.; Levine, R.; Grimes, H. L.; more...
    Leukemia (2023)

    Fulltext@MSK | Save